Health Care Cost

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

PVI for intermittent claudication was associated with more than double the rate of major adverse limb events and higher costs of care.

gMG rescue therapy hinges on hospital access; grocery aid cuts diabetes complications; trials, CAR T strain oncology; myeloma faces logistics barriers.

Experts discuss what SCAN Health Plan's new Medicare Advantage (MA) partnership with Costco could mean for beneficiaries, competition, and costs.

Poor cardiovascular health, especially high BMI and poor sleep, is linked to a substantially higher risk of overactive bladder, new data show.

This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

AHIP's Jeanette Thornton details health care's prior authorization commitments as a 2027 real-time approval target approaches.

Medicare Part D changes, premium stabilization expiration, and a Bridge demonstration converge with rising GLP-1 demand and costs.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

FDA clears Roche and Eli Lilly's first blood test to both rule in and rule out amyloid pathology in Alzheimer disease.

Employer health care costs are projected to rise 9.5% in 2027, surpassing $19,000 per employee amid persistent medical and drug spending pressures.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.